Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trialSara A. Hurvitz, Javier Cortés, Roberto Hegg et al.|The Lancet|2022Cited by 664
Hyperactivation of mTORC1 signaling mediates folliculin deficiency–induced pulmonary cyst formation in Birt-Hogg-Dubé syndromeKe Cao, Wei Shi, Jianhua Zhang et al.|Journal of Clinical Investigation|2026Cited by 3